NEXTGEN HEALTHCARE INC (NXGN) Stock Fundamental Analysis
USA - NASDAQ:NXGN - US65343C1027 - Common Stock
23.94 USD
+0.03 (+0.13%)
23.93 USD
-0.01 (-0.04%)
Taking everything into account, NXGN scores 4 out of 10 in our fundamental rating. NXGN was compared to 35 industry peers in the Health Care Technology industry. NXGN has only an average score on both its financial health and profitability. NXGN has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year NXGN was profitable.
In the past year NXGN has reported a negative cash flow from operations.
Of the past 5 years NXGN 4 years were profitable.
NXGN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of NXGN (-0.72%) is better than 78.57% of its industry peers.
Looking at the Return On Equity, with a value of -1.47%, NXGN is in the better half of the industry, outperforming 78.57% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 0.82%, NXGN is in the better half of the industry, outperforming 78.57% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for NXGN is below the industry average of 6.80%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.72% | ||
| ROE | -1.47% | ||
| ROIC | 0.82% |
ROA(3y)0.48%
ROA(5y)1.41%
ROE(3y)0.64%
ROE(5y)2.06%
ROIC(3y)1.91%
ROIC(5y)2.95%
1.3 Margins
NXGN has a better Operating Margin (1.06%) than 78.57% of its industry peers.
NXGN's Operating Margin has declined in the last couple of years.
NXGN's Gross Margin of 46.40% is in line compared to the rest of the industry. NXGN outperforms 42.86% of its industry peers.
In the last couple of years the Gross Margin of NXGN has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.06% | ||
| PM (TTM) | N/A | ||
| GM | 46.4% |
OM growth 3Y-58.31%
OM growth 5Y-27.53%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.93%
GM growth 5Y-2.66%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), NXGN is destroying value.
Compared to 1 year ago, NXGN has less shares outstanding
NXGN has more shares outstanding than it did 5 years ago.
NXGN has a worse debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 3.59 indicates that NXGN is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.59, NXGN is in the better half of the industry, outperforming 78.57% of the companies in the same industry.
A Debt/Equity ratio of 0.63 indicates that NXGN is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.63, NXGN is doing worse than 66.67% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.63 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 3.59 |
ROIC/WACC0.08
WACC10.14%
2.3 Liquidity
NXGN has a Current Ratio of 2.52. This indicates that NXGN is financially healthy and has no problem in meeting its short term obligations.
NXGN has a Current ratio of 2.52. This is comparable to the rest of the industry: NXGN outperforms 50.00% of its industry peers.
NXGN has a Quick Ratio of 2.52. This indicates that NXGN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.52, NXGN is in line with its industry, outperforming 52.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.52 | ||
| Quick Ratio | 2.52 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 33.33% over the past year.
NXGN shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 6.96% yearly.
NXGN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.25%.
Measured over the past years, NXGN shows a small growth in Revenue. The Revenue has been growing by 4.23% on average per year.
EPS 1Y (TTM)33.33%
EPS 3Y5.69%
EPS 5Y6.96%
EPS Q2Q%24%
Revenue 1Y (TTM)13.25%
Revenue growth 3Y6.53%
Revenue growth 5Y4.23%
Sales Q2Q%10.65%
3.2 Future
The Earnings Per Share is expected to grow by 17.15% on average over the next years. This is quite good.
The Revenue is expected to grow by 7.76% on average over the next years.
EPS Next Y14.49%
EPS Next 2Y17.83%
EPS Next 3Y17.28%
EPS Next 5Y17.15%
Revenue Next Year11.2%
Revenue Next 2Y9.22%
Revenue Next 3Y8.41%
Revenue Next 5Y7.76%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 21.38 indicates a rather expensive valuation of NXGN.
Compared to the rest of the industry, the Price/Earnings ratio of NXGN indicates a rather cheap valuation: NXGN is cheaper than 92.86% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 27.20. NXGN is valued slightly cheaper when compared to this.
The Price/Forward Earnings ratio is 17.59, which indicates a rather expensive current valuation of NXGN.
NXGN's Price/Forward Earnings ratio is rather cheap when compared to the industry. NXGN is cheaper than 92.86% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.70, NXGN is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.38 | ||
| Fwd PE | 17.59 |
4.2 Price Multiples
NXGN's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. NXGN is cheaper than 71.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 34.12 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
NXGN's earnings are expected to grow with 17.28% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.48
PEG (5Y)3.07
EPS Next 2Y17.83%
EPS Next 3Y17.28%
5. Dividend
5.1 Amount
NXGN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
23.94
+0.03 (+0.13%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners0%
Inst Owner Change0%
Ins Owners31.12%
Ins Owner Change0%
Market Cap1.61B
Analysts50.77
Price Target24.41 (1.96%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly Dividend0.71
Dividend Growth(5Y)3.39%
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.08%
Min EPS beat(2)6.95%
Max EPS beat(2)23.21%
EPS beat(4)3
Avg EPS beat(4)7.54%
Min EPS beat(4)-6.17%
Max EPS beat(4)23.21%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-0.77%
Min Revenue beat(2)-2.26%
Max Revenue beat(2)0.72%
Revenue beat(4)2
Avg Revenue beat(4)-0.33%
Min Revenue beat(4)-2.26%
Max Revenue beat(4)2.24%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.11%
PT rev (3m)16.34%
EPS NQ rev (1m)-2.38%
EPS NQ rev (3m)-0.97%
EPS NY rev (1m)0%
EPS NY rev (3m)0.55%
Revenue NQ rev (1m)0.33%
Revenue NQ rev (3m)-0.1%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.06%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.38 | ||
| Fwd PE | 17.59 | ||
| P/S | 2.31 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 3.8 | ||
| P/tB | 94.94 | ||
| EV/EBITDA | 34.12 |
EPS(TTM)1.12
EY4.68%
EPS(NY)1.36
Fwd EY5.68%
FCF(TTM)-0.65
FCFYN/A
OCF(TTM)-0.11
OCFYN/A
SpS10.36
BVpS6.31
TBVpS0.25
PEG (NY)1.48
PEG (5Y)3.07
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.72% | ||
| ROE | -1.47% | ||
| ROCE | 1.04% | ||
| ROIC | 0.82% | ||
| ROICexc | 1.14% | ||
| ROICexgc | 5.45% | ||
| OM | 1.06% | ||
| PM (TTM) | N/A | ||
| GM | 46.4% | ||
| FCFM | N/A |
ROA(3y)0.48%
ROA(5y)1.41%
ROE(3y)0.64%
ROE(5y)2.06%
ROIC(3y)1.91%
ROIC(5y)2.95%
ROICexc(3y)2.27%
ROICexc(5y)3.46%
ROICexgc(3y)18.71%
ROICexgc(5y)23.54%
ROCE(3y)2.41%
ROCE(5y)3.74%
ROICexcg growth 3Y-50.16%
ROICexcg growth 5Y-31.62%
ROICexc growth 3Y-56.26%
ROICexc growth 5Y-28.38%
OM growth 3Y-58.31%
OM growth 5Y-27.53%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.93%
GM growth 5Y-2.66%
F-Score2
Asset Turnover0.81
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.63 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 5.98 | ||
| Cap/Depr | 95.52% | ||
| Cap/Sales | 5.14% | ||
| Interest Coverage | 1.1 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.52 | ||
| Quick Ratio | 2.52 | ||
| Altman-Z | 3.59 |
F-Score2
WACC10.14%
ROIC/WACC0.08
Cap/Depr(3y)75.15%
Cap/Depr(5y)68.18%
Cap/Sales(3y)5.17%
Cap/Sales(5y)5.06%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.33%
EPS 3Y5.69%
EPS 5Y6.96%
EPS Q2Q%24%
EPS Next Y14.49%
EPS Next 2Y17.83%
EPS Next 3Y17.28%
EPS Next 5Y17.15%
Revenue 1Y (TTM)13.25%
Revenue growth 3Y6.53%
Revenue growth 5Y4.23%
Sales Q2Q%10.65%
Revenue Next Year11.2%
Revenue Next 2Y9.22%
Revenue Next 3Y8.41%
Revenue Next 5Y7.76%
EBIT growth 1Y-70.75%
EBIT growth 3Y-55.58%
EBIT growth 5Y-24.47%
EBIT Next Year47.96%
EBIT Next 3Y27.47%
EBIT Next 5Y21.11%
FCF growth 1Y-203.01%
FCF growth 3Y-52.24%
FCF growth 5Y-32.4%
OCF growth 1Y-110.78%
OCF growth 3Y-20.1%
OCF growth 5Y-10.01%